Semaglutide (GLP-1 Analogue) -5mg (Lyophilized)

Semaglutide is a glucagon-like peptide-I receptor agonist (GLP-1 RA)

THE PRODUCTS PURCHASED ON THIS WEBSITE ARE INTENDED FOR RESEARCH CHEMICAL USE ONLY. These products are not intended to be used for human or animal consumption and/or ingestion of any kind. These products should not be used as food additives, drugs or household chemicals. These products should only be used by Qualified Professionals. Bodily introduction into Human and Animals of any kind is strictly forbidden by law. All the product information on this website is for educational purposes only.

 Semaglutide (GLP-1) Peptide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied for its therapeutic benefits, particularly in the management of type 2 diabetes and obesity.

Research studies, including large-scale clinical trials like the SUSTAIN and PIONEER programs, have investigated the effects of semaglutide. The peptide’s primary mechanism of action involves mimicking the activity of endogenous GLP-1, leading to enhanced insulin secretion, reduced glucagon secretion, slowed gastric emptying, and increased feelings of satiety.

One of the key areas of interest in semaglutide research is its impact on glycemic control. By activating GLP-1 receptors, the peptide promotes glucose-dependent insulin secretion, helping to lower blood sugar levels in individuals with type 2 diabetes. Clinical trials, such as the SUSTAIN program, have demonstrated the efficacy of semaglutide in achieving and maintaining glycemic control, often leading to improvements in HbA1c levels.

In addition to its effects on glucose metabolism, semaglutide has shown promise in the management of obesity. The STEP clinical trials have investigated the use of semaglutide as a potential weight loss treatment. The results have indicated significant reductions in body weight in individuals with obesity, making semaglutide a notable option for addressing both type 2 diabetes and obesity simultaneously.

While semaglutide has shown positive outcomes in terms of glycemic control and weight loss, ongoing research is essential for a comprehensive understanding of its long-term efficacy, safety profile, and potential applications beyond the currently studied conditions. It’s recommended to consult the latest scientific literature and clinical trial updates for the most recent information on semaglutide.

Sources:

• Aroda VR, et al. (2017). Once-weekly semaglutide versus once-daily sitagliptin for patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
• Davies M, et al. (2017). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

THE PRODUCTS PURCHASED ON THIS WEBSITE ARE INTENDED FOR RESEARCH CHEMICAL USE ONLY. These products are not intended to be used for human or animal consumption and/or ingestion of any kind. These products should not be used as food additives, drugs or household chemicals. These products should only be used by Qualified Professionals. Bodily introduction into Human and Animals of any kind is strictly forbidden by law. All the product information on this website is for educational purposes only.